



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/16, 9/20, 9/48, 47/14, 47/26		A1	(11) International Publication Number: WO 99/42086 (43) International Publication Date: 26 August 1999 (26.08.99)
<p>(21) International Application Number: PCT/EP99/00994</p> <p>(22) International Filing Date: 16 February 1999 (16.02.99)</p> <p>(30) Priority Data: 98/02143 23 February 1998 (23.02.98) FR</p> <p>(71) Applicant (<i>for all designated States except US</i>): MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250, D-64293 Darmstadt (DE).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): SASLAWSKI, Olivier [FR/FR]; 43, rue de Sèze, F-69006 Lyon (FR). GIET, Philippe [FR/FR]; 9, place Tobie Robatel, F-69001 Lyon (FR). MICHEL, Dominique [FR/FR]; 284, rue André Philip, F-69003 Lyon (FR). HULOT, Thierry [FR/FR]; 24, rue Jarente, F-69002 Lyon (FR).</p> <p>(74) Common Representative: MERCK PATENT GMBH; Postfach, D-64271 Darmstadt (DE).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: ORALLY ADMINISTRABLE IMMEDIATE-RELEASE AND PROLONGED-RELEASE GALENIC FORM COMPRISING AN ABSORPTION-PROMOTING AGENT AND USE OF THIS ABSORPTION-PROMOTING AGENT</p> <p>(57) Abstract</p> <p>The present invention relates to an orally administrable galenic form allowing improved absorption by the transmembrane or paracellular route in the gastrointestinal tract of active ingredients which are hydrophilic or ionizable in physiological media, comprising at least one such active ingredient, an absorption-promoting agent having an HLB greater than 8, the said absorption-promoting agent consisting of one or more lipid substances chosen from: polysorbates; ethers of polyoxyethylene and alkyl; esters of polyoxyethylene and fatty acids; fatty acids; fatty alcohols; bile acids and their salts with pharmaceutically acceptable cations; esters of C₁-C₆ alkanol with fatty acids; esters of polyol with fatty acids, the said polyol comprising from 2 to 6 hydroxyl functional groups; and polyglycolysed glycerides; in combination with one or more pharmaceutically acceptable excipients, the pharmaceutical forms comprising captopril being excluded.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IR	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Cote d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent

5 The invention relates to orally administrable galenic forms comprising one or more active ingredients which are hydrophilic or ionizable in physiological media in combination with one or more excipients. These galenic forms are preferably solid forms such as tablets or
10 gelatin capsules. The galenic compositions of the invention are particularly advantageous in that they allow improved absorption of active ingredients which are hydrophilic and/or ionizable in physiological media, by the transmembrane or paracellular route,
15 because of their particular excipient composition.

The absorption of orally administered active ingredients essentially takes place by the transmembrane or paracellular route at the level of the mucous membranes of the gastrointestinal tract. In the
20 case of active ingredients which are hydrophilic or ionizable in physiological media, the absorption predominantly takes place by the paracellular route. Because of this, the bioavailability of this type of active ingredient is very low, the kinetics of
25 absorption being very slow. Numerous authors have more precisely studied the kinetics of absorption of active ingredients in the form of calcium salts and have observed that the transport of these substances by the paracellular route is very limited: it appears that the
30 calcium salts have the effect of closing again the channels present between the cells which provide for transport by the paracellular route. Reference may be made, for example, to P. Artursson and C. Magnusson, J. Pharm. Sci., 79, 595, 1990 and S.G. Milton and V.P.
35 Knutson, J. Cell. Physiol., 144, 498, 1990.

The use of various excipient systems comprising liquid or amphiphilic compounds such as semisynthetic glycerides for promoting the absorption of active substances has been abundantly illustrated in the art.

- 2 -

In this regard, there may be mentioned the following state of the art documents: WO 93/00891, EP 670 166, WO 95/08 983, WO 94/23 733 and WO 96/21 439. All the prior art formulations are intended, however, to 5 improve the bioavailability of lipophilic active substances. Moreover, the formulations provided in the case of tablets, granules or microgranules do not always allow control of the kinetics of release.

This may result in an intense increase in the 10 plasma concentration, which is quite often followed, in the case of compounds having a short half-life, by a rapid decrease in these levels which reach values below the therapeutic threshold. Multiplication of the number of doses is then necessary in order to maintain a 15 therapeutic effect for the medication.

However, control of the absorption of the active ingredients at the level of the gastrointestinal tract will ensure the efficacy of the therapy used. Furthermore, modulation of the release (while 20 preserving an optimized absorption) makes it possible to ensure better therapeutic cover and to improve tolerance and compliance. Thus, it is possible to reduce the number of doses of the medicament and to thereby ensure compliance with the treatment. This is 25 essential in the case of treatment of long-term, or even chronic, disorders or pathologies.

The galenic forms of the invention allow improvement in the absorption of the active ingredients which are hydrophilic and/or ionizable in physiological 30 media, the control of the kinetics of release and the maintenance of the yield of absorption, this being also in the case of solid pharmaceutical forms such as tablets, gelatin capsules or microgranules.

Although the galenic forms of the invention are 35 particularly appropriate for the administration of active substances which are hydrophilic and/or ionizable in physiological media, they are also suitable for the administration of lipophilic substances.

- 3 -

It may also be noted that the pharmaceutical dosage forms of the invention ensure excellent reproducibility of the results, while allowing increased control of the rate of release during the 5 phase of prolonged release of the active ingredient. By using the pharmaceutical dosage forms of the invention, it becomes possible to optimize the availability of the active ingredients in the body taking into account both the tolerance of the subject to the active ingredient 10 and the pharmacokinetic and metabolic profiles of the active ingredient.

The tablets of the invention are moreover advantageous from the point of view of the formulation of the active ingredients since a judicious choice of 15 the excipients leads to tablets with high concentrations of active ingredients.

The invention provides more precisely orally administrable galenic forms comprising an active ingredient which is hydrophilic and/or ionizable in 20 physiological media, an absorption-promoting agent having an HLB (hydrophilic/lipophilic balance value) greater than 8 and one or more pharmaceutically acceptable excipients.

It should be understood that the galenic forms comprising captopril as active ingredient are excluded from 25 the subject of the invention.

According to the invention, the absorption-promoting agent consists of one or more lipid substances chosen from:

- polysorbates; ethers of polyoxyethylene and 30 alkyl; esters of polyoxyethylene and fatty acids; fatty acids; fatty alcohols; bile acids and their salts with pharmaceutically acceptable cations; esters of C₁-C₆ alkanol with fatty acids; esters of polyol with fatty acids, the said polyol comprising from 2 to 6 hydroxyl functional 35 groups; polyglycolysed glycerides.

These lipid substances are of natural or synthetic origin, or alternatively are obtained by semisynthesis. A good number of them are commercially available or are easily prepared from commercial products.

- 4 -


Although the inventors do not intend to be limited to any mechanism of action, it is thought that by acting on the surface tension of biological fluids, these substances act on membrane contacts at the level of the cells of the 5 gastrointestinal mucous membrane. Whatever the case, it is thought that the absorption-promoting agent creates in situ an environment with modified lipophilicity.

The polysorbates are esters of fatty acids of polyethoxylated sorbitan. Polyethoxylated sorbitan offers 10 polyethoxylated sorbitol and polyethoxylated sorbitol anhydrides. The expression "polysorbate" designates both mono- and polyesters of fatty acids. Preferably, the polysorbates used according to the invention are mono-, di- or triesters of saturated or unsaturated fatty acids, in 15 which the fatty acids are preferably C₈-C₂₂, better still C₁₂-C₁₈. There may be mentioned more particularly monolaurate, monopalmitate, mono- and tristearate, monooleate and monoisostearate.

Preferably, the polysorbates used are the product 20 of the esterification of fatty acids with the copolymer of a molecule of sorbitol or of one of its anhydrides and of 3 to 30 molecules of ethylene oxide.


By way of example, the structural formulae of a monoester and of a triester are given below:

25



polyethoxylated sorbitan monoester

- 5 -



polyethoxylated sorbitan triester

where R is the residue of a fatty acid and x, y, z and
 5 w are integers whose sum varies between 3 and 30,
 preferably between 4 and 20.

Generally, polysorbates will be used whose
 molecular weight varies between 450 and 2000, better
 still between 500 and 1900.


10 Such polysorbates are commercially available,
 especially under the trade name Tween®.

The ethers of polyoxyethylene and alkyl have
 the general formula:



in which x is an integer between 8 and 22, preferably
 between 12 and 18, and y is an integer from 10 to 60.
 Among these compounds, there may be mentioned monocetyl
 20 ether of polyethylene glycol, monolauryl ether of
 polyethylene glycol, monooleyl ether of polyethylene
 glycol and monostearyl ether of polyethylene glycol.
 These compounds are commercially available, especially
 under the trade name Brij®.

25 The esters of polyoxyethylene and fatty acids
 are either fatty acid monoesters of the formula:



where R represents the residue of a fatty acid and n the degree of polymerization of the polyethoxylated chain,
or fatty acid diesters of formula:

5



where R and n are as defined above,
or mixtures of these monoesters and of these diesters.
10 These compounds are commonly prepared from the corresponding fatty acids and polyethylene glycols.

The polyethylene glycols used as starting material have variable average molecular masses of between 100 and 7000, preferably between 150 and 6000.
15 The starting fatty acids are saturated or unsaturated and generally have from 8 to 22 carbon atoms, better still from 12 to 18 carbon atoms. The esters of polyoxyethylene and fatty acid are especially marketed by the company AKZO-NOBEL.

20 The fatty alcohols which can be used according to the invention are saturated or unsaturated, and have preferably from 8 to 22 carbon atoms, better still from 12 to 18 carbon atoms.

The fatty acids are saturated or unsaturated,
25 and have preferably from 8 to 22 carbon atoms, or better still from 12 to 18 carbon atoms.

The bile acids are well known to persons skilled in the art. There may be mentioned glycocholic acid and taurodeoxycholic acid as preferred bile acids.
30 Within the framework of the invention, the promoting agent may comprise a bile acid salt obtained by reacting this acid with a pharmaceutically acceptable base. The salts of alkali and alkaline-earth metals are particularly advantageous, such as sodium glycocholate.

35 The esters of C₁-C₆ alkanol with fatty acids can also be used as absorption-promoting agent. Preferably, the fatty acids leading to these esters are as defined above.

- 7 -

The polyol esters are obtained by condensation of one or more fatty acids, as defined above, with a polyol comprising 2 to 6 hydroxyl functional groups. Among these esters, those obtained by esterification of 5 glycols, polyglycerols, sorbitol or its anhydrides are particularly preferred. As glycol, propylene glycol may be mentioned.

The esters of sorbitol or of its anhydrides with one or more fatty acids are fatty acid esters of 10 sorbitan, especially marketed under the trade mark Span®.

The polyglycolysed glycerides are mixtures of glycerides of fatty acids and of esters of polyoxyethylene with fatty acids. In these mixtures, the fatty 15 acids are saturated or unsaturated C₈-C₂₂, for example C₈-C₁₂ or C₁₆-C₂₀. The glycerides are mono-, bi- or triglycerides or mixtures thereof in any proportions. Polyglycolysed glycerides are marketed especially by the company Gattefosse under the trade names Labrafil®, 20 Labrasol and Gélucire®.

According to the invention it is essential that the absorption-promoting agent has an HLB greater than 8. Preferably, the HLB is greater than 10; better still it varies between 12 and 16. It should be understood 25 that when the absorption-promoting agent consists of a mixture of several lipid substances, it is the mixture of these substances which should have an HLB greater than 8.

The preferred galenic forms of the invention 30 are those for which the absorption-promoting agent comprises at least one polyglycolised glyceride, especially at least one polyglycolysed glyceride having an HLB of between 12 and 16.

Advantageously, the absorption-promoting agent 35 comprises, in combination with one or more polyglycolysed glycerides, an ester of sorbitan with one or more fatty acids. By way of illustration, the absorption-promoting agent consists of a mixture of one or more polyglycolysed glycerides and a sorbitan ester

with a C₈-C₂₂ fatty acid, preferably a C₁₆-C₂₀ fatty acid also having an HLB of between 12 and 16. Among the preferred sorbitan esters, there may be mentioned sorbitan monolaurate, sorbitan trilaurate, sorbitan 5 monoisostearate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesqui-isostearate, sorbitan sesqui-oleate, sorbitan trioleate and sorbitan tristearate.

Particularly advantageous examples are:

10 - an absorption promoter consisting of Gélucire® 44/14;

15 - an absorption promoter consisting of a mixture of Gélucire® 44/14 and Labrasol®;

20 - an absorption promoter consisting of a mixture of Gélucire® 44/14, Labrasol® and an ester of sorbitan with a C₁₆-C₂₀ unsaturated fatty acid, such as sorbitan trioleate.

It should be noted that the lipid substances constituting the absorption-promoting agent may also 25 play the role of lubricant, of wetting agent, of thickening agent or of plasticizer.

Thus, glyceryl monostearate and glyceryl palmitostearate have a good lubricating power. Glyceryl 30 monooleate and the fatty acid esters of polyethoxylated sorbitan play the role of wetting agent and the C₁₆-C₂₀ fatty alcohols and fatty acids (stearic acid, cetyl alcohol), glycerol palmitostearate and more generally some fatty acid glycerides among the monoglycerides, diglycerides and triglycerides are also thickeners. In the same manner, the medium- or short-chain triglycerides act as plasticizers.

Finally, the esters of fatty acid and sorbitan (marketed for example under the name Span®) and the fatty acid esters of polyethoxylated sorbitan (marketed 35 for example under the name Tween®) can be used as additives which may be incorporated into the semisolid matrix for filling gelatin capsules.

The galenic forms of the invention are more particularly intended to improve the absorption of


active ingredients which are hydrophilic and/or ionizable in physiological media corresponding to at least one of the following definitions:

5 (A) active ingredients comprising at least one and generally two functional groups chosen from carboxylic acid, sulphonic acid, phosphoric acid, phosphonic acid, phosphinic acid and phenol functional groups in free form or ionized form with pharmacologically acceptable cations;

10 (B) the active ingredients comprising at least one and generally two functional groups chosen from the sulphonic acid, phosphoric acid, phosphonic acid and phosphinic acid functional groups in free form or ionized form with pharmacologically acceptable cations;


15 (C) the active ingredients in the form of calcium salts;

(D) the active ingredients which have the formula (I)



in which

X is chosen from:




R being a C₁-C₇ alkyl radical,

R₁, R₂, R₃ are chosen from hydrogen and a C₁-C₇ alkyl radical,


30 A represents a group of formula:

- 10 -



with v and w = 0, 1, 2
or a group of formula

5



R₅, R₆ being chosen, independently of each other, from hydrogen, a C₁-C₇ alkyl radical, an aryl radical having from 6 to 14 carbon atoms and a heteroaryl radical chosen from furyl, thienyl and thiazolyl, it being possible for the aryl and heteroaryl radicals to carry 1 to 3 substituents chosen from a C₁-C₇ alkyl group, a halogen or a trifluoromethyl group, and t = 1-3,

R₄ is chosen from hydrogen, a C₁-C₇ alkyl radical, a CF₃ radical, an aryl radical having from 6 to 14 carbon atoms and a heteroaryl radical chosen from furyl, thienyl and thiazolyl, it being possible for the aryl and heteroaryl radicals to carry 1 to 3 substituents chosen from a C₁-C₇ alkyl group, a halogen or a trifluoromethyl group,

M represents a monovalent metal (Na, K, Li) or a divalent metal (Ca, Mg, Sr, Zn),


m = 1 or 2,

p = 1-2 and q = 1-2, p and q being such that the electrical neutrality of the salt is ensured.


Among these, the following are particularly preferred:

- those for which X =

30



- those for which X =



5 - the following compounds:

calcium 3-acetylamino-1-propanesulphonate (or calcium acamprosate)

calcium 3-(2-(methyl)propanoylamino)propanesulphonate

magnesium 3-(2-(methyl)propanoylamino)propanesulphonate

10 calcium 3-(butanoylamino)propanesulphonate

magnesium 3-(butanoylamino)propanesulphonate

calcium 3-(acetylamino)pentanesulphonate

calcium 3-(pentanoylamino)propanesulphonate

calcium 3-(benzoylamino)propanesulphonate

15 magnesium 3-(benzoylamino)propanesulphonate

strontium 3-(acetylamino)propanesulphonate

zinc 3-(2-(methyl)propanoylamino)propanesulphonate

strontium 3-(2-(methyl)propanoylamino)propanesulphonate

calcium 3-(3-(methyl)propanoylamino)propanesulphonate

20 magnesium 3-(3-(methyl)butanoylamino)propanesulphonate

calcium 3-(2,2-(dimethyl)propanoylamino)propane-
sulphonate

magnesium 3-(2,2-(dimethyl)propanoylamino)propane-
sulphonate

25 calcium 3-(acetylamino)-2-methylpropanesulphonate

calcium 3-(acetylamino)-3-methylpropanesulphonate

magnesium 3-(acetylamino)-3-methylpropanesulphonate

calcium 3-(acetylamino)-1-methylpropanesulphonate

calcium 3-(acetylamino)-2-phenylpropanesulphonate

30 calcium 2-(2-acetylaminomethyl)phenylmethanesulphonate

calcium N-(methyl-3-(acetylamino)propanesulphonate

calcium (3-(acetylamino)propyl)ethylphosphinate

calcium 3-(acetylamino)-2-dimethylpropanesulphonate

calcium 3-(trifluoromethylcarbonyl)propanesulphonate;

35 (E) the active ingredients which are guanidines
or guanylguanidines such as metformin or any one of its

pharmaceutically acceptable salts and especially metformin hydrochloride;

5 (F) the active ingredients which are pharmacologically acceptable salts of primary, secondary and tertiary amines, such as hydrochlorides, hydrobromides, maleates, acetates, succinates, propionates, fumarates and oxalates;

10 (G) the active ingredients which, in free form or ionized form with the pharmacologically acceptable cations or anions present in the physiological media, have a solubility greater than 100 g, preferably greater than 250 g per litre;

15 (H) the active ingredients which, in free form or ionized form with the pharmacologically acceptable cations or anions present in the physiological media, have a partition coefficient D (octanol/water) corresponding to the relationship $\log_{10}D < 0$, preferably $\log_{10}D < -0.5$, or better still $\log_{10}D < -20$.

20 The partition coefficient D is determined in a conventional manner using the "shake flask" technique.

25 A known quantity of product is introduced into a container containing octanol and water in equal parts (100 ml of water; 100 ml of octanol; the quantity of active ingredient being about 10^{-3} M). The mixture is stirred until the product reaches its equilibrium state between the two phases. The phases are then separated. The product may be assayed in both phases by various known methods adapted to the nature of the active ingredient (spectrometry, chromatographic techniques).

30 The partition coefficient D is given by the equation:

$$\text{Log D} = \log (\text{Coct}/\text{Caq})$$

35 where Coct: concentration of active ingredient in the octanolic phase;
Caq: concentration of active ingredient in the aqueous phase.

- 13 -

As particularly preferred active ingredients, there may be mentioned metformin and acamprosate as well as their pharmacologically acceptable salts.

5 The pharmacologically acceptable salts are those commonly used in the art. The alkali and alkaline-earth metal salts are examples.

10 The quantity of active ingredient present in the galenic forms of the invention varies between 0.001 and 95% by weight, preferably between 0.01 and 90%, or better still between 0.1 and 90%.

15 Depending on the desired effect, persons skilled in the art will incorporate into the galenic compositions of the invention a larger or smaller quantity of absorption-promoting agent. In the general case, the ratio of the active ingredient(s) to the absorption-promoting agent is between 0.001 and 10, for example between 0.01 and 10.

20 The galenic forms of the invention may be provided in a solid form of the tablet or gelatin capsule type. When the galenic form is a tablet, the ratio of the active ingredient(s) to the absorption-promoting agent is between 1 and 10.

25 When the galenic form is a gelatin capsule, the ratio of the active ingredient(s) to the absorption-promoting agent is between 0.1 and 2.

30 The tablets according to the invention may comprise, in combination with the absorption-promoting agent, one or more additional excipients so as to obtain mono- or polyphase tablets. Persons skilled in the art will choose these excipients according to the desired final properties, the application envisaged or so as to overcome a disadvantage linked to the method of manufacturing the tablets.

35 These excipients exist especially among the following categories: diluents, binders, lubricants, antioxidants, colorants, sweeteners, flavourings and acidulants, wetting agents, hydrophilizing agents such as sorbitol and cyclodextrins, osmotic agents such as mannitol, pH regulators, stabilizing agents such as

trehalose and mannitol, adsorbents, chelating and sequestering agents and gastro-resistant film-coating excipients of the type including cellulose acetyl phthalate and polymethacrylates.

5 By way of example, any one of the following diluents or a combination thereof may be chosen: calcium carbonate, calcium sulphate, sucrose, dextrates, dextrin, dextrose, dicalcium phosphate dihydrate, kaolin, magnesium carbonate, magnesium 10 oxide, maltodextrin, cellulose, microcrystalline cellulose, sorbitol, starches, pregelatinized starch, talc, tricalcium phosphate and lactose.

Among the binders, there may be mentioned: gum arabic, gum tragacanth, guar gum, alginic acid, sodium 15 alginate, sodium carboxymethylcellulose, dextrin, gelatin, hydroxyethylcellulose, hydroxypropylcellulose, liquid glucose, magnesium and aluminium silicate, maltodextrin, povidone, pregelatinized starch, starch and zein.

20 The lubricants are glidants (such as anhydrous colloidal silicate, magnesium trisilicate, magnesium silicate, cellulose, starch, talc or tricalcium phosphate) or alternatively antifriction agents (such as calcium stearate, hydrogenated vegetable oils, 25 paraffin, magnesium stearate, polyethylene glycol, sodium benzoate, sodium lauryl sulphate, fumaric acid, stearic acid or zinc stearate and talc).

As examples of antioxidants, persons skilled in the art can select any of the following compounds: 30 ascorbic acid, ascorbyl palmitate, fumaric acid, propyl gallate, sodium ascorbate and sodium metabisulphite, alpha-tocopherol, malic acid, butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA).

Preferred wetting agents are:

35 • sodium docusate and sodium lauryl sulphate which are anionic surfactants;

• benzalkonium chloride, benzethonium chloride and cetrimide, which are cationic surfactants;

- polyvinyl alcohol and sorbitans, which are non-ionic surfactants.

Among the pH regulators, there may be mentioned acidifiers of the type including citric acid, hydrochloric acid, lactic acid, tartaric acid, as well as alcalinizing agents of the type including monoethanolamine, diethanolamine and triethanolamine, potassium citrate, sodium bicarbonate, sodium citrate dihydrate.

Examples of adsorbants are bentonite, anhydrous colloidal silica, kaolin, magnesium and aluminium silicate, microcrystalline cellulose and cellulose.

As chelating and sequestering agents, there may be used citric acid monohydrate, edetic acid, disodium phosphate, monosodium phosphate, potassium citrate, tartaric acid and sodium citrate dihydrate.

The quantities of these additives are those usually used in the art. In general, the binder may represent from 0.5 to 25% by weight, or better still from 2 to 5% by weight of the tablet.

The lubricants are preferably incorporated into this tablet in an amount of 0.01 to 10% by weight.

As a guide, the quantity of gastro-resistant film-coating excipients varies between 0.5 and 9% by weight of the tablet.

These tablets may be bare, but are preferably film-coated. The film-coating envisaged will make it possible to avoid an unpleasant taste by bringing about masking of the taste. It may participate in modifying the release of the active ingredient and/or of the promoting agent. A gastro-resistant film-coating will make it possible to avoid any release in the stomach; a film-coating which is more hydrophobic and insensitive to pH variations will contribute more towards extending the kinetics of dissolution. Depending on the role attributed to the film-coating, persons skilled in the art will be able to choose the film-forming agent from among the following categories: cellulose derivatives such as hydroxypropylmethylcellulose (HPMC), ethyl cellulose, cellulose acetophthalate, cellulose

acetopropionate, cellulose trimelliate, the polymers and copolymers of methacrylic acid and its derivatives.

The film-forming agent may be supplemented with:

- 5 • plasticizers (such as polyoxyethylene glycols of high molecular weight, esters of polyacids such as citric acid or phthalic acid)
- fillers (such as talc, metal oxides such as titanium oxide)
- colorants chosen from those usable and approved by 10 the pharmaceutical and food industries.

The tablets of the invention are conventionally prepared by a method including the steps of granulation followed by compression. More precisely, the method of manufacture which is the subject of the invention 15 comprises the steps consisting in:

- a) preparing a granule of an active substance from a pulverulent mixture of the active substance, to which there would have been added the absorption-promoting agent, preferably in liquid form, agents modifying the 20 kinetics of dissolution, a binding agent and any other excipient which persons skilled in the art will judge to be necessary. The granule formed is called the inner phase.
- b) preparing, where appropriate, a pulverulent mixture, 25 termed outer phase, comprising for example cohesion agents, glidants, lubricants.
- c) combining, by mixing, the inner and outer phases. It should be noted that all of the constituents of the outer phase may be added and mixed with the excipients 30 of the inner phase during the preparation of the granule ready to be compressed.
- d) forming the tablet by compressing the mixture.

Step (a) involves the granulation of powders of amorphous or crystallized particles. This granulation 35 is carried out in a manner known per se and, for example, by a wet granulation method.

The granulation method comprises five essential steps: (i) dry mixing of the various constituents, (ii)

wetting, (iii) actual granulation, (iv) drying, and then (v) sizing.

The dry mixing consists of mixing the pulverulent excipients entering into the composition of 5 the granules.

The wetting consists of adding to the pulverulent mixture the various constituents, a wetting liquid which may be water, or an aqueous or organic solution of binder or an alcohol. This is carried out 10 in a mixer-kneader of the planetary, roller, projection or whirling type or a mixer-granulator of the rapid type.

In step (a), the appropriate wetting liquid is water or an alcohol or an aqueous or organic solution 15 of binder, as generally recommended in the art.

According to a particularly preferred embodiment, the absorption-promoting agent is used as wetting liquid for the granulation.

The drying may be carried out in an oven, or in 20 a fluidized air bed dryer, or by microwave.

According to a preferred embodiment of the invention, the sizing is carried out by passing over a screen with a mesh opening of between 0.5 and 1.5 mm, preferably between 0.8 and 1.5 mm.

25 A preferred mesh opening value is 1.25 mm.

However, the invention does not intend to be limited to the use of a wet granulation method. Thus, persons skilled in the art will also be able to use other existing granulation methods, such as the dry 30 granulation method.

The last step of compression (step d) on an alternating or rotary machine leads to the formation of the tablet.

The galenic forms of the invention may be 35 provided in the form of gelatin capsules or any other substitute material, which may be monolithic, mono- or polyphasic. The content of the gelatin capsule is a matrix of the semisolid type. In this matrix, the active ingredient may be present in dissolved form or

alternatively in suspension. The said matrix comprises the absorption-promoting agent described above, the active ingredient and optionally one or more additional excipients chosen from those described below so as to 5 give the preparation the desired properties or so as to overcome the disadvantages linked to the process of preparing the gelatin capsules.

The additional excipients which may be incorporated into the semisolid matrix in combination 10 with the mixture of absorption-promoting agents are of the following categories.

- Wetting agents among which are phospholipids such as the derivatives of phosphatidylcholine or phosphatidylethanolamine better known by the name of natural or purified lecithins
- Anionic surfactants, such as sodium alkylsulphonates (such as sodium lauryl sulphate or sodium docusate), cationic surfactants such as quaternary ammoniums (such as benzalkonium chloride or benzethonium chloride or cetrimide)
- Thickening agents of the lipid type, among which are vegetable oils (cotton seed, sesame and groundnut oils) and derivatives of these oils (hydrogenated oils such as hydrogenated castor oil, glycerol behenate).
- Thickening agents of the waxy type such as natural carnauba wax or natural beeswax, synthetic waxes such as cetyl ester waxes.
- Thickening agents of the amphiphilic type such as polymers of ethylene oxide (polyoxyethylene glycol of high molecular weight between 4000 and 100000) or propylene and ethylene oxide copolymers (poloxamers).
- Thickeners of the cellulosic type (semisynthetic derivatives of cellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxymethylcellulose, of high molecular weight and high viscosity, gum) or any other polysaccharide such as alginic acid.

- Thickeners of the polymeric type such as acrylic acid polymers (such as carbomers).
- Thickeners of the mineral type such as colloidal silica, bentonite.

5 • Antioxidants such as ascorbic acid, ascorbyl palmitate, fumaric acid, sodium ascorbate, sodium metabisulphite.

It will be noted that the thickening agents may be added to the mixture of promoting agents in an 10 amount of 0.1 per 1 to 10 per 1. The ratio which exists between the mixture of promoting agents and the mixture of thickening agents determines directly, for the same active ingredient, the kinetics of dissolution of the latter.

15 The monolithic gelatin capsules of the invention are conventionally prepared by a method including a phase of preparing a semisolid matrix followed by casting into a gelatin capsule.

20 More precisely, the semisolid matrix is prepared by dispersing, with stirring, the active ingredient in the mixture of the various excipients. The use of subsidiary heating of the container of mixture may be necessary in order to maintain this mixture of excipients in a liquid or semi-pasty state 25 until the phase of casting into a gelatin capsule.

Furthermore, it may be envisaged to cast successively in the same gelatin capsule several semisolid matrices, differing from each other by their active ingredient and/or excipient compositions, thus 30 making possible immediate- and prolonged-type releases which can be adjusted according to pharmacokinetic criteria.

Finally, the method of manufacture may be completed, where appropriate, by sealing the gelatin 35 capsule by bandrolling or any other equivalent system.

It should also be noted that the gelatin capsule form may be replaced by a soft gelatin capsule form or any other substitute material. All the information cited above for the gelatin capsule, both

20

in terms of composition and preparation of the semisolid matrix, remain applicable in this case.

The galenic forms of the invention may be provided in the form of microgranules which may be 5 packaged in a unit dose such as a gelatin capsule, a cachet or a sachet, or even a vial. In this case, the microgranules are obtained by combining the active ingredient and the absorption-promoting agent with one or more excipients chosen from the following 10 categories:

- Diluents such as calcium carbonate, calcium sulphate dihydrate, sucrose, lactose, dextrates, dextrin, dextrose, dicalcium phosphate dihydrate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, 15 microcrystalline cellulose, sorbitol, mannitol, starches, talc, tricalcium phosphate.
- Thickening agents of the lipid type, among which are vegetable oils (cotton seed, sesame and groundnut oils) and derivatives of these oils (hydrogenated oils such as hydrogenated castor oil, glycerol behenate).
- Thickening agents of the waxy type such as natural carnauba wax or natural beeswax, synthetic waxes such as cetyl ester waxes.
- 25 • Thickening agents of the amphiphilic type such as polymers of ethylene oxide (polyoxyethylene glycol of high molecular weight between 4000 and 100000) or propylene and ethylene oxide copolymers (poloxamers).
- Thickeners of the cellulosic type (semisynthetic 30 derivatives of cellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxymethylcellulose, of high molecular weight and high viscosity, gum) or any other polysaccharide such as alginic acid.
- 35 • Thickening agents of the polymeric type such as acrylic acid polymers (such as carbomers).
- Thickening agents of the mineral type such as colloidal silica, bentonite.

21

- Antioxidants such as ascorbic acid, ascorbyl palmitate, fumaric acid, sodium ascorbate, sodium metabisulphite.
- Effervescent mixtures are some of the agents capable of being incorporated into the microgranules. These mixtures are composed, on the one hand, of alkali or alkaline-earth metal carbonates or sodium glycinate carbonate, and, on the other hand, of organic acids such as citric acid or tartaric acid. Polymers of the cellulosic type (hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxymethylcellulose, of high molecular weight and high viscosity) or any other polysaccharide such as alginic acid or of polyacrylic type (carbomers) may also be used in combination. This combination makes it possible to obtain microgranules having good floatability in biological media.

These microgranules may be bare, but are preferably film-coated. The film-coating envisaged will make it possible to avoid an unpleasant taste by bringing about masking of the taste. It may participate in modifying the release of the active ingredient and/or of the promoting agent. A gastro-resistant film-coating will make it possible to avoid any release in the stomach; a film-coating which is more hydrophobic and insensitive to pH variations will contribute more towards extending the kinetics of dissolution. Depending on the role attributed to the film-coating, persons skilled in the art will be able to choose the film-forming agent from among the following categories: cellulose derivatives such as hydroxypropylmethylcellulose, ethyl cellulose, cellulose acetophthalate, cellulose acetopropionate, cellulose trimellitate, the polymers and copolymers of methacrylic acid and its derivatives. The film-forming agent will be supplemented with:

- plasticizers (such as polyoxyethylene glycols of high molecular weight, esters of polyacids such as citric acid or phthalic acid)

- fillers (such as talc, metal oxides such as titanium oxide)
- colorants chosen from those usable and approved by the pharmaceutical and food industries.

5 The rate of film-coating may vary from 2 to 25% of the weight of the bare microgranules, preferably from 4 to 20% and more preferably from 5 to 20%.

10 Furthermore, it may be envisaged to fill the same gelatin capsule with different types of micro-
10 granules, differing from each other by their active ingredient and/or absorption-promoting agent and/or excipient compositions, or to even combine bare and film-coated microgranules, making it possible to adjust the kinetics of release of the active ingredient.

15 The microgranules are conventionally prepared by a method including incorporation of the mixture of absorption-promoting agents with the pulverulent mixture of the other excipients and of the active ingredient(s) into a high-speed mixer, followed by
20 nucleation, swelling and spheronization.

25 As regards the film-coating phase, it is conventionally carried out by spraying a suspension of film-forming agent and additives over a mass of moving microgranules in a turbine or more advantageously in a fluidized air bed apparatus.

30 The microgranules or a mixture thereof are placed in gelatin capsules in conventional manner using a filling device. For the latter operation, the incorporation of additives such as glidants, lubricants or even diluents may prove necessary. Persons skilled in the art will be able to choose either of these compounds from among the excipients cited in the corresponding paragraphs above.

35 It should be noted that the microgranules may have a size of between 0.1 and 3 mm, preferably between 0.2 and 2 mm and more preferably between 0.3 and 1.5 mm.

Furthermore, it is possible to envisage the production of tablets from the preceding microgranules.

In this case, the cohesion of the tablets can be ensured by virtue of the addition of other microgranules or of a granule prepared in a conventional manner with the excipients conventionally used for this 5 purpose.

In order to easily control the kinetics of release of the active ingredient, it is desirable to incorporate one or more of the following constituents into the galenic forms of the invention:

- 10 - glycerol palmitostearate;
- a hydrogenated castor oil;
- glycerol behenate; or
- stearic acid.

The addition of polymeric derivatives may also 15 be envisaged for this purpose.

As appropriate polymeric substance, there may be mentioned semisynthetic celluloses of high molecular weight, carboomers such as polyacrylic acids, polymers and copolymers of methacrylic acid and its derivatives.

20 The examples provided in the remainder of this text illustrate the invention in greater detail. This will be done with reference to Figures 1 to 9.

For the sake of simplicity, all the formulations described below have 500-mg doses of active 25 ingredient.

In the following examples, the active ingredient is calcium acamprosate (or calcium acetylhomotaurinate) designated ACA in the text which follows.

30 Precirol® and Precirol ATO5® are glycerol palmitostearate marketed by the company Gattefosse.

Compritol® is glycerol behenate marketed by the company Gattefosse.

Methocel K15M® is hydroxypropylcellulose 35 marketed by the company Colorcon.

24

Eudragit RS 30D® is a copolymer of acrylic acid ester and methacrylic acid esters, containing a low content of ammonium groups available from the company Rohm.

5 Example 1

Gelatin capsule containing a semisolid matrix providing immediate release of the active ingredient.

The constituents for the preparation of the immediate-release semisolid matrix were used in the 10 following proportions (by weight):

- ACA 54%
- Gélucire 44/14® 45%
- Soya bean lecithin 1%

The excipients are melted at a temperature 15 greater than their melting point, their mixture is homogenized and then the active ingredient is incorporated. The mixture is cast into gelatin capsules of size 00 in a sufficient quantity.

Example 2

20 Dissolution profile for the gelatin capsules manufactured according to the procedure of Example 1

The dissolution profiles for the gelatin capsules manufactured in the preceding example were determined after assaying by high-performance liquid 25 chromatography.

The gelatin capsules to be tested are introduced into reactors which were each previously filled with one litre of distilled water, at 37°C, and provided with a temperature regulating system and an 30 efficient stirring system.

During the whole experiment, the reactor is kept stirred at 37°C.

At regular time intervals t , samples of the medium contained in the reactor are collected, filtered 35 on a membrane of porosity 0.45 μm (Millex HA, in cellulose acetate) and analysed by high-performance liquid chromatography (HPLC) with detection by UV spectrophotometry.

Conditions for analysis by HPLC.

25

- Column having a length of 10 cm and an internal diameter of 4.6 mm, filled with 5- μ m particles of octadecylsilylated silica
- Mobile phase: tetrabutylammonium perchlorate solution at 341.9 mg in 1000 ml of a water/acetonitrile: 95/5 mixture
- The detection is carried out by UV spectrophotometry at 200 nm.

10 The quantity q of active ingredient present in the sample is determined by comparison with the area of the peak obtained under the same conditions with a reference solution of known concentration. A simple calculation makes it possible to find the total quantity of active ingredient released into the reactor 15 at the instant t .

16 The dissolution profile of the gelatin capsule is obtained by plotting on a curve the calculated quantities of active ingredient (expressed in percentage of the nominal dose) as a function of time. 20 (See Figure 1).

Example 3

Gelatin capsules containing a semisolid matrix providing immediate release of the active ingredient.

21 The table below gives the composition by weight 25 of each of the gelatin capsules

Composition	Gelatin capsule 3.1	Gelatin capsule 3.2	Gelatin capsule 3.3	Gelatin capsule 3.4	Gelatin capsule 3.5	Gelatin capsule 3.6
ACA	47%	47%	51%	51%	51%	50%
Gélucire 44/14 [®]	39%	39%	30%	28%	25%	30%
Labrasol [®]	13%	-	18%	20%	23%	18%
PEG 400	-	13%	-	-	-	-
Sorbitan trioleate	-	-	-	-	-	2%
Soya bean lecithin	1%	1%	1%	1%	1%	-
HLB	14	14	14	14	14	13.5

The procedure is the same as that of Example 1.

Example 4

5 Gelatin capsules containing a semisolid matrix providing prolonged release of the active ingredient. The table below gives the composition by weight of each of the gelatin capsules

Composition	Gelatin capsule 4.1	Gelatin capsule 4.2
ACA	54%	54%
Gélucire 44/14 [®]	32%	22.5%
Précিrol [®]	13%	22.5%
Soya bean lecithin	1%	1%

10

The procedure is the same as that of Example 1.

Example 5

Gelatin capsules containing a semisolid matrix providing prolonged release of the active ingredient.

15 The table below gives the composition by weight of each of the gelatin capsules.

Composition	Gelatin capsule 5.1	Gelatin capsule 5.2	Gelatin capsule 5.3	Gelatin capsule 5.4	Gelatin capsule 5.5
ACA	54%	54%	54%	54%	54%
Gélucire 44/14 [®]	38%	36%	34%	32%	29%
Précিrol [®]	7%	9%	11%	13%	16%
Soya bean lecithin	1%	1%	1%	1%	1%

The procedure is the same as that of Example 1.

5 The dissolution profiles obtained for these gelatin capsules by applying the analytical method of Example 2 are given in Figure 2.

Example 6

10 Gelatin capsules containing a semisolid matrix providing prolonged immediate release of the active ingredient.

15 Gelatin capsules were filled both with a matrix obtained according to Example 1 and a matrix obtained according to Example 4, gelatin capsule 4.5. The weight ratio of the matrix of Example 1 to the matrix of Example 4 is 1:2.

Example 7

Gelatin capsules filled with microgranules for immediate release of the active ingredient.

20 The constituents for the preparation of the immediate-release microgranules were used in the following proportions by weight:

Composition	Gelatin capsule 7.1	Gelatin capsule 7.2	Gelatin capsule 7.3
ACA	50%	75%	85%
Gélucire 44/14	16%	14%	15%
Lactose	34%	11%	-

The pulverulent active ingredient and the excipient are introduced into a mixer of the rapid type. After the phases of melting of the excipient and then nucleation followed by swelling of the granules, 5 the latter are spheronized.

The dissolution profile obtained for the gelatin capsule 7.2 by applying the analytical method of Example 2 is given in Figure 3.

Example 8

10 Gelatin capsules filled with microgranules for immediate release of the active ingredient.

The constituents for the preparation of the immediate-release microgranules were used in the following proportions (by weight):

15 • ACA 85%
• Gélucire 50/13® 15%

The method of manufacture which served for the manufacture of the microgranules of Example 7 was also used in this example.

20 **Example 9**

Gelatin capsule filled with microgranules for the prolonged release of the active ingredient.

The constituents for the preparation of the immediate-release microgranules were used in the 25 following proportions (by weight):

• ACA 25%
• Préciprol® 18%
• Lactose 57%

The method of manufacture which served for the 30 manufacture of the microgranules of Example 7 was also used in this example.

The dissolution profile obtained for this gelatin capsule by applying the analytical method of Example 2 is given in Figure 4.

35 **Example 10**

Gelatin capsules filled with microgranules for the prolonged release of the active ingredient.

The constituents for the preparation of the prolonged-release microgranules were used in the following proportions by weight:

Composition	Gelatin capsule 10.1	Gelatin capsule 10.2	Gelatin capsule 10.3
ACA	75%	75%	75%
Gélucire 50/13®	7%	3.5%	1%
Compritol®	7%	10.5%	13%
Lactose	11%	11%	11%

5 The method of manufacture which served for the manufacture of the microgranules of Example 7 was also used in this example.

10 The dissolution profiles obtained for these gelatin capsules by applying the analytical method of Example 2 are given in Figure 5.

Example 11

Gelatin capsules filled with microgranules with high floatability.

15 The constituents for the preparation of these microgranules were used in the following proportions by weight:

- ACA 50%
- Gélucire 44/14® 9%
- Précirol ATO 5® 9%
- 20 • Methocel K15 M® 15%
- Citric ac. 4%
- Na bicarbonate 8%
- Lactose 5%

25 The method of manufacture which served for the manufacture of the microgranules of Example 7 was also used in this example.

Example 12

Gelatin capsules filled with microgranules for the prolonged release of the active ingredient.

The constituents for the preparation of the prolonged-release microgranules were used in the following proportions:

- ACA 74%
- 5 • Gélucire 44/14® 13%
- Eudragit RS 30D® 9%
- Talc 3%
- Triethyl citrate 1%

The manufacture can be separated into two
10 stages:

The microgranules obtained in Example 7.3 were film-coated using the following suspension of film-forming agent,

- Suspension of Eudragit RS 30D® 250 g
- 15 • Talc 22.50 g
- Triethyl citrate 11.25 g
- Distilled water 260 g

The film-coating operation is carried out in a fluidized air bed apparatus.

20 Example 13

Gelatin capsules filled with microgranules for the prolonged release of the active ingredient.

The constituents for the preparation of the prolonged-release microgranules were used in the
25 following proportions by weight:

Composition	Gelatin capsule 13.1	Gelatin capsule 13.2	Gelatin capsule 13.3
ACA	80%	74%	66%
Gélucire 44/14®	14%	13%	12%
Ethyl cellulose	6%	13%	22%

The manufacture can be separated into two stages:

The microgranules obtained in Example 7.3 were film-coated using the following suspension of film-forming agent,

- Surelease® (aqueous suspension of ethyl cellulose) 300 g
- Distilled water 200 g

5

The film-coating operation is carried out in a fluidized air bed apparatus.

The dissolution profiles obtained for these gelatin capsules by applying the analytical method of Example 2 10 are given in Figure 6.

Example 14

Gelatin capsules filled with two types of microgranules for the immediate and prolonged release of the active ingredient.

15 The constituents for the preparation of the immediate- and prolonged-release microgranules were used in the following proportions:

	ACA	78%
20	Gélucire 44/14®	14%
	Ethyl cellulose	8%

25 The gelatin capsules were prepared by filling with a mixture of bare microgranules (obtained in Example 7.3) and of the film-coated microgranules (obtained in Example 13.2). The weight ratio of the microgranules of Example 7.3 to the microgranules of Example 13.2 is 40:60.

30 The dissolution profile obtained for this gelatin capsule by applying the analytical method of Example 2 is given in Figure 7.

Example 15

Tablets for the immediate and prolonged release of the active ingredient.

The constituents for the preparation of the tablets for immediate and prolonged release were used in the following proportions by weight:

Composition	Tablet 15.1	Tablet 15.2	Tablet 15.3	Tablet 15.4
ACA	50%	50%	50%	50%
Gélucire 44/14®	10%	10%	10%	10%
Compritol®	20%	20%	10%	10%
Micro-crystalline cellulose	9%	14%	19%	24%
Povidone	10%	5%	10%	5%
Mg stearate	1%	1%	1%	1%

5

The active ingredient is introduced into a rapid mixer-granulator, the molten Gélucire is added with stirring.

10 Compritol®, povidone and microcrystalline cellulose are then added to this pulverulent mixture which is subjected to stirring. The wetting liquid, purified water, is then added until well-formed granules and agglomerates are obtained.

15 The whole is then dried (oven or fluidized air bed) and sized on a screen with a mesh opening of 1.25 mm.

The dry granule is introduced into a rapid mixer-granulator, and then magnesium stearate is added.

20 The lubricated granule is compressed on a rotary machine equipped, for example, with oblong dies.

The dissolution profiles obtained for these tablets by applying the analytical method of Example 2 are given in Figure 8.

Example 16

25 Tablets for the immediate and prolonged release of the active ingredient.

The constituents for the preparation of these tablets were used in the following proportions by weight:

Composition

5 Bare core

	ACA	50%
	Gélucire 44/14®	10%
	Compritol®	10%
	Microcrystalline cellulose	19%
10	Povidone	10%
	Mg stearate	1%

Film-coating

	HPMC	64%
15	PEG 4000	15%
	Talc	21%

The method of manufacture comprises two stages. The preparation of the bare cores is carried out as in 20 Example 15; it is followed by film-coating in a turbine by spraying a suspension.

Example 17

Tablets for the immediate and prolonged release of the active ingredient.

25 The constituents for the preparation of these tablets were used in the following proportions by weight:

Composition

Bare core

30	ACA	47.5%
	Gélucire 44/14®	9.5%
	Compritol®	9.5%
	Microcrystalline cellulose	18%
	Povidone	9.5%
35	Mg stearate	1%
	Talc	5%

Film-coating

HPMC	64%
PEG 4000	15%
Talc	21%

5

The method of manufacture comprises two stages. The preparation of the bare cores is carried out as in Example 15; it is followed by film-coating in a turbine by spraying a suspension.

10 The dissolution profile obtained for this tablet by applying the analytical method of Example 2 is given in Figure 9.

Example 18

15 Actions of various promoting agents or mixtures of promoting agents on the permeability of calcium acetylhomotaurinate, in the Caco-2 cellular model.

20 A solution of carbon 14-labelled acamprosate, of known concentration, is placed in the apical compartment of a Grass Sweetana-type diffusion chamber which comprises a second so-called basolateral compartment separated from the first by an insert supporting a monocellular confluent culture of human colon adenocarcinoma endothelium epithelial cells, Caco-2 line.

25 Samples are collected at regular intervals from the second basolateral compartment. The acamprosate concentration is determined by scintigraphy. A simple calculation makes it possible to obtain the apparent permeability coefficient (Papp). The acamprosate 30 solution is supplemented with various promoting agents or mixtures of promoting agents, under varying conditions. The influence of these agents on the apparent permeability coefficient (Papp) was measured. The experimental results are grouped together in the 35 following table where the apparent permeability coefficient values (Papp) are expressed in cm/s.

Action of the absorption-promoting agents:
Appearance Permeability Coefficient

Category of Absorption-Promoting Agent	Géluclire					PEG	Fatty Ac	Labrafil	Na glyco cholate	Polysorbate 80
Type	44/14		37/02		4000	Caprylic	Caprylic	1944 cs		
Conc. (% m/v)	0.10	1.0	5.0	1	5	0.25	0.25	1.0	5.0	0.2
P _{APP} (10 ⁻⁵ cm/s)										
Mean (n=6)	24.0	152.0	618.6	1030	47.0	55.8	58.5	12.3	63.6	94.3
Standard deviation	1.1	12.9	21.1	216.0	9.2	9.4	30.7	1.2	11.0	17.6

Example 19

36

Increase in the bioavailability of calcium acetylhomotaurinate in Beagle dogs by means of an immediate-release oral form.

5 The relative bioavailability of calcium-acetylhomotaurinate was determined after administration of various immediate-release oral formulations, and in comparison with a reference formulation: gastroresistant tablets at 333 mg.

10 Protocol:

The study was carried out on 5 dogs of Beagle breed. On the day of the administration, the dogs, starved from the day before, successively received at an interval of one week, by the oral route, one of the following 15 galenic forms:

Formulation	Dose of acamprosate per unit (mg)	Number of units administered
Reference formulation (1)	333	2
Reference tablet supplemented with 100 mg of sodium glycocholate (2)	333	2
Gelatin capsule with semisolid matrix of Example 1	500	1
Floating tablet at 500 mg (3)	500	1
Immediate-release gelatin capsule with micro-granules of Example 7.1	500	1

(1) Unit composition of the reference tablet 1

Cores

20 • Acamprosate 333 mg
 • Crospovidone 10 mg
 • Microcrystalline cellulose 100 mg
 • Magnesium silicate 30 mg

	• <i>Starch glycolate</i>	10 mg
	• <i>Colloidal silica</i>	3 mg
	• <i>Magnesium stearate</i>	7 mg
<i>Film-coating</i>		
5	• <i>Eudragit L 30D</i>	27.9 mg
	• <i>Talc</i>	6.5 mg
	• <i>Propylene glycol</i>	4.2 mg

10 (2) *Unit composition of the tablets supplemented with sodium glycocholate 2*

	<i>Cores</i>	
	• <i>Acamprosate</i>	333 mg
	• <i>Sodium glycocholate</i>	100 mg
	• <i>Crospovidone</i>	10 mg
15	• <i>Microcrystalline cellulose</i>	100 mg
	• <i>Magnesium silicate</i>	30 mg
	• <i>Starch glycolate</i>	10 mg
	• <i>Colloidal silica</i>	3 mg
	• <i>Magnesium stearate</i>	7 mg
20	<i>Film-coating</i>	
	• <i>Eudragit L 30D</i>	27.9 mg
	• <i>Talc</i>	6.5 mg
	• <i>Propylene glycol</i>	4.2 mg

25 (3) *Unit composition of floating tablets at 500 mg.*

	• <i>Acamprosate</i>	500 mg
	• <i>Hydroxypropylmethylcellulose</i>	550 mg
	• <i>Povidone</i>	80 mg
	• <i>Microcrystalline cellulose</i>	80 mg
30	• <i>Sodium bicarbonate</i>	250 mg
	• <i>Talc</i>	7 mg
	• <i>Magnesium stearate</i>	6 mg

35 Blood samples were collected just before the administration, and then 0.5; 1; 2; 3; 4; 5; 6; 8 and 24 hours after the administration. Using these samples, plasma acamprosate was assayed by gas chromatography/mass spectrometry (GC/MS). The following

38 pharmacokinetic parameters were then determined for each administered form:

Maximum value of plasma acamprosate (Cmax), area under the curve of the plasma concentrations 5 (AUC), relative bioavailability of the oral form tested (F), established according to the formula:

$$10 \quad F = \frac{\text{Dose (reference)} \times \text{AUC (tested)}}{\text{dose (tested)} \times \text{AUC (reference)}}$$

The mean pharmacokinetic parameters observed for each of the forms tested are presented in the table below:

15

Formulation	C max (ng/ml)	F (ref. 666 mg) %
Reference formulation 2 tablets at 333 mg	17,593	100
2 tablets at 333 mg supplemented with 100 mg of sodium glycocholate	7921	68
Gelatin capsule with semisolid matrix of Example 1	16,935	138
Floating tablet at 500 mg	15,072	138
Immediate-release gelatin capsule with micro-granules of Example 7.1	19,543	146

Table 1: Mean pharmacokinetic parameters for acamprosate observed in Beagle dogs after single oral administration of various immediate-release galenic 20 forms versus the reference form.

Conclusion:

The gelatin capsule form containing semisolid matrix of Example 1 and the immediate-release gelatin capsule form filled with microgranules of Example 7.1 allow an 5 increase of about 40% in the relative bioavailability of calcium acetylhomotaurinate.

Example 20

Increase in the bioavailability of calcium acetylhomotaurinate in Beagle dogs by means of a 10 prolonged-release oral form.

The relative bioavailability of calcium acetylhomotaurinate was determined after administration of various prolonged-release oral formulations, and in comparison with two reference formulations: 15 gastroresistant tablets at 500 mg and a formulation in the form of immediate-release gelatin capsules (Example 1). Furthermore, comparison of the plasma levels at 6 and 24 hours was carried out for all the forms tested.

20

Protocol: The study was carried out on 6 dogs of Beagle breed. On the day of the administration, the dogs, starved from the day before, successively received at an interval of one week, by the oral route, one of the 25 following galenic forms:

Formulation	Dose per unit (mg)	Number of units administered
Reference 1: gastro resistant tablet (1)	500	2
Reference 2: immediate-release gelatin capsule with semisolid matrix Example 1	500	1
Prolonged-release matrix tablet Example 15.3	500	1
Prolonged-release gelatin capsule with semisolid matrix Example 4.1	500	1
Prolonged-release gelatin capsule with semisolid matrix Example 4.2	500	1
Gelatin capsule with microgranules Example 14	500	1

(1) Unit composition of the gastroresistant 500-mg tablets

Cores

5	• Acamprosate	500 mg
	• Crospovidone	15 mg
	• Microcrystalline cellulose	150 mg
	• Magnesium silicate	45 mg
	• Starch glycolate	15 mg
10	• Colloidal silica	4.5 mg
	• Magnesium stearate	10.5 mg
	Film-coating	
	• Eudragit L 30D	31.1 mg
	• Talc	7.2 mg
15	• Propylene glycol	4.5 mg

20 Blood samples were collected just before the administration, and then 0.5; 1; 2; 3; 4; 5; 6; 8 and 24 hours after the administration. Using these samples, plasma acamprosate was assayed according to an LC/MS method. The following pharmacokinetic parameters were then determined for each administered form:

25 Maximum value of plasma acamprosate (Cmax), the plasma levels at 6 hours (C(6h)) and at 24 hours (C(24h)). area under the curve of the plasma concentrations (AUC), relative bioavailability of the oral form tested (F), established according to the formula:

$$30 F = \frac{\text{Dose(reference)} \times \text{AUC(tested)}}{\text{dose(tested)} \times \text{AUC(reference)}}$$

Result:

35 The mean pharmacokinetic parameters observed for each of the forms tested are presented in the table below:

Mean	C _{max} (ng/ml)	Frel. (%)	C(6h)	C(24h)
Reference 2: immediate-release gelatin capsule with semisolid matrix Example 1	20,868	100	3433	69
Gelatin capsule with microgranules Example 14	12,448	67	2448	32
Prolonged-release matrix tablet Example 15.3	20,753	99	3916	261
Prolonged-release gelatin capsule with semisolid matrix Example 4.1	19,175	111	4471	82
Prolonged-release gelatin capsule with semisolid matrix Example 4.2	9363	64	3470	99

Table 2: Mean pharmacokinetic parameters for acamprosate observed in Beagle dogs after single oral 5 administration of various modified-release galenic forms versus an immediate form.

Conclusions:

The matrix tablet form (Example 15.3) and the semisolid 10 gelatin capsule form (Example 4.1) make it possible to maintain or even increase the relative bioavailability of acamprosate, and furthermore the levels observed respectively at 6 h and 24 h are greater than those observed for the reference gelatin capsule: Example 1.

15

Example 21

Evaluation of the relative bioavailability, of the pharmacokinetic parameters and of the tolerance of two forms of acamprosate versus the reference form 20 (2 x 500 mg) after a single administration by the oral route. Open and crossover studies in 18 healthy male volunteers.

The relative bioavailability of two galenic forms containing 500 mg of calcium acetylhomotaurinate 25 was evaluated in men in comparison with a reference formulation, also containing 500 mg but of which 2 unit doses were administered.

42
Summary of the study:

The following products were randomly administered to 18 healthy subjects, of male sex, of Caucasian origin, aged from 18 to 45 years:

- 5 • a reference product R: 2 immediate-release gastro-resistant tablets containing 500 mg doses (on an empty stomach)
- a so-called "floating" tablet F containing a 500 mg dose (not on an empty stomach)
- 10 • a gelatin capsule G with semisolid matrix containing a 500 mg dose: Example 1 (on an empty stomach)

Unit composition of the 500 mg gastroresistant tablets: R

Cores

- 15 • Acamprosate 500 mg
- Crospovidone 15 mg
- Microcrystalline cellulose 150 mg
- Magnesium silicate 450 mg
- Starch glycolate 15 mg
- 20 • Colloidal silica 4.5 mg
- Magnesium stearate 10.5 mg
- Film-coating*
- Eudragit L 30D 31.1 mg
- Talc 7.2 mg
- 25 • Propylene glycol 4.5 mg

Unit composition of the floating tablets at 500 mg: F

- Acamprosate 500 mg
- Hydroxypropylmethylcellulose 550 mg
- 30 • Povidone 80 mg
- Microcrystalline cellulose 80 mg
- Sodium bicarbonate 250 mg
- Citric acid 100 mg
- Talc 7 mg
- 35 • Colloidal silica 3.2 mg
- Magnesium stearate 6 mg

Blood samples were collected at the following times:

0 - 0.5 - 1 - 1.5 - 2 - 3⁴³ - 4 - 5 - 6 - 8 - 10 - 12 - 14
 - 16 - 24 - 36 - 48 and 72 hours.

5 The samples were assayed according to a method by gas-liquid chromatography coupled to mass spectrometry with detection by mass fragmentometry.

Using the plasma values obtained, the following variables were calculated:

- the area under the curve (AUC),
- the maximum plasma concentration (C_{max}),
- 10 • the time for obtaining the maximum plasma concentration (T_{max}) of acamprosate.
- The relative bioavailability (F) obtained using the following equation:

15
$$F = \frac{Dose(reference) \times AUC(tested)}{dose(tested) \times AUC(reference)}$$

Results:

20 All the pharmacokinetic parameters observed for the mean kinetic values are presented in Table 3:

Mean CV%	Dose mg	T _{max} (h)	C _{max} (ng/ml)	C ₂₄ (ng/ml)	F (%)
Reference R	1000	4.3	248	60	100
Floating tablet F	500	3.4	278	28	121
Gelatin capsule G	500	1.1	1725	29	274

Table 3: Mean pharmacokinetic parameters observed after a single oral administration of various immediate oral 25 forms of acamprosate to 16 young healthy volunteers.

Conclusion:

The formulation in the form of a gelatin capsule with semisolid matrix makes it possible to 30 obtain a larger plasma peak which indicates potentiation of the absorption which thereby causes an

increase in bioavailability by a factor of 2.74
relative to a formulation in the form of a conventional
gastroresistant tablet.

45
CLAIMS


1. Orally administerable galenic form allowing improved absorption by the transmembrane or paracellular route in the gastrointestinal tract of 5 active ingredients which are hydrophilic or ionizable in physiological media, comprising at least one active ingredient, an absorption-promoting agent having an HLB greater than 8, the said absorption-promoting agent consisting of one or more lipid substances chosen from:
 - 10 - polysorbates; ethers of polyoxyethylene and alkyl; esters of polyoxyethylene and fatty acids; fatty acids; fatty alcohols; bile acids and their salts with pharmaceutically acceptable cations; esters of C₁-C₆ alkanol with fatty acids; esters of polyol with fatty acids, the said polyol comprising from 2 to 6 hydroxyl functional groups; polyglycolysed glycerides; in combination with one or more pharmaceutically acceptable excipients, the pharmaceutical dosage forms comprising captopril being excluded.
 - 20 2. Galenic form according to Claim 1, characterized in that the active ingredient which is hydrophilic or ionizable in physiological media comprises at least one functional group chosen from carboxylic acid, sulphonic acid, phosphonic acid, 25 phosphoric acid, phosphinic acid and phenol functional groups in free form or ionized form with pharmacologically acceptable cations.
 - 30 3. Galenic form according to Claim 2, characterized in that the active ingredient which is hydrophilic or ionizable in physiological media comprises at least one functional group chosen from sulphonic acid, phosphoric acid, phosphonic acid and phosphinic acid functional groups in free form or ionized form with pharmacologically acceptable cations.
 - 35 4. Galenic form according to Claim 1, characterized in that it comprises an active ingredient in the form of a calcium salt.
 5. Galenic form according to Claim 1, characterized in that the active ingredient which is

hydrophilic or ionizable⁴⁶ in physiological media is a guanidine or a guanylguanidine.

6. Galenic form according to any one of the preceding claims, characterized in that the said active 5 ingredient, free or in its ionized form with the cations or the anions present in the physiological media has a solubility greater than 100 g, preferably greater than 250 g/l.

7. Galenic form according to any one of Claims 1 10 to 5, characterized in that the said active ingredient, free or in its ionized form with the cations or the anions present in the physiological media has a partition coefficient D (octanol/water) corresponding to the relationship $\log_{10}D < -0.5$, preferably $\log_{10}D < 15 -20$.


8. Galenic form according to any one of Claims 1 to 3, characterized in that the active ingredient is a compound of formula:



(I)

20 in which


X is chosen from:




25 R being a C₁-C₇ alkyl radical,

R₁, R₂, R₃ are chosen from hydrogen and a C₁-C₇ alkyl radical,

A represents a group of formula:



with v and w = 0, 1, 2
or a group of formula



5 R₅, R₆ being chosen, independently of each other, from hydrogen, a C₁-C₇ alkyl radical, an aryl radical having from 6 to 14 carbon atoms and a heteroaryl radical chosen from furyl, thienyl and thiazolyl, it being possible for the aryl and heteroaryl radicals to carry
10 1 to 3 substituents chosen from a C₁-C₇ alkyl group, a halogen or a trifluoromethyl group, and t = 1-3,
R₄ is chosen from hydrogen, a C₁-C₇ alkyl radical, a CF₃ radical, an aryl radical having from 6 to 14 carbon atoms and a heteroaryl radical chosen from furyl,
15 thienyl and thiazolyl, it being possible for the aryl and heteroaryl radicals to carry 1 to 3 substituents chosen from a C₁-C₇ alkyl group, a halogen or a trifluoromethyl group,
M represents a monovalent metal (Na, K, Li) or a
20 divalent metal (Ca, Mg, Sr, Zn),
m = 1 or 2,
p = 1-2 and q = 1-2, p and q being such that the electrical neutrality of the salt is ensured.
9. Galenic form according to Claim 8,
25 characterized in that the active ingredient has the formula (I) in which


X =



10. Galenic form according to Claim 8,
30 characterized in that the active ingredient has the formula (I) in which

X =

48



11. Galenic form according to Claim 8, characterized in that the active ingredient which is 5 hydrophilic or ionizable in physiological media is calcium acamprosate.
12. Galenic form according to Claim 5, characterized in that the active ingredient which is 10 hydrophilic or ionizable in physiological media is metformin or one of its pharmaceutically acceptable salts, especially its hydrochloride.
13. Galenic form according to any one of the preceding claims, characterized in that the absorption-promoting agent has an HLB greater than 10 and 15 preferably of between 12 and 16.
14. Galenic form according to any one of the preceding claims, characterized in that the polyol esters with fatty acids are chosen from the esters of glycols, the esters of polyglycerols and the esters of 20 sorbitol and of its anhydrides.
15. Galenic form according to any one of the preceding claims, characterized in that the absorption-promoting agent comprises at least one polyglycolyzed glyceride, preferably a polyglycolysed glyceride having 25 an HLB of between 12 and 16.
16. Galenic form according to any one of the preceding claims, characterized in that the absorption-promoting agent comprises at least one polyglycolysed glyceride and generally a sorbitan ester with one or 30 more fatty acids.
17. Galenic form according to Claim 16, characterized in that the absorption-promoting agent consists of a mixture of one or more polyglycolyzed glycerides and generally a sorbitan ester with a 35 saturated or unsaturated C₈-C₂₂ fatty acid, preferably a C₁₀-C₁₄ fatty acid.

18. Galenic form according to any one of the preceding claims, characterized in that the weight ratio of the active ingredient to the absorption-promoting agent is between 0.001 and 10.

5 19. Galenic form according to Claim 18, which is a tablet in which the weight ratio of the active ingredient to the absorption-promoting agent is between 1 and 10.

10 20. Galenic form according to Claim 18, which is a gelatin capsule in which the weight ratio of the active ingredient to the absorption-promoting agent is between 0.1 and 2.

15 21. Galenic form according to any one of the preceding claims, characterized in that it comprises, in addition, an agent allowing the control of the kinetics of release of the active ingredient chosen from glycerol palmitostearates, glycerol behenates, hydrogenated castor oils and mixtures thereof.

20 22. Use of an absorption-promoting agent in the preparation of an orally administerable pharmaceutical dosage form, for improving the absorption by the transmembrane or paracellular route in the gastrointestinal tract of active ingredients which are hydrophilic or ionizable in physiological media,

25 characterized in that the absorption-promoting agent is as defined in any one of Claims 1 and 12 to 16.

23. Use according to Claim 22, characterized in that the active ingredient which is hydrophilic or ionizable in physiological media is as defined in any 30 one of Claims 2 to 11.


24. Use according to either of Claims 22 and 23, characterized in that the weight ratio of the active ingredient to the absorption-promoting agent is between 0.01 and 10.

35 25. Method of preparing a galenic form according to any one of Claims 1 to 19 and 2 in the form of a tablet comprising (i) a first step of preparing, by the wet route, a granule of an active substance from a pulverulent mixture of the active substance and various

excipients, and (ii) a ⁵⁰ second step of compressing, the said method being characterized in that the absorption-promoting agent is used in step (i) as wetting liquid.

1/7


Fig.1



SUBSTITUTE SHEET (RULE 26)

2/7

Fig. 2



SUBSTITUTE SHEET (RULE 26)

3 / 7




Fig.3




Fig.4

4/7

Fig.5






Fig.6



5/7



SUBSTITUTE SHEET (RULE 26)

6/7





Fig.8

7/7

Fig.9



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

Inten. Application No
PCT/EP 99/00994

A. CLASSIFICATION F SUBJECT MATTER
 IPC 6 A61K9/16 A61K9/20 A61K9/48 A61K47/14 A61K47/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SWENSON E. ET AL: "Intestinal permeability enhancement: efficacy, acute local toxicity and reversibility" PHARM. RES., vol. 11, no. 8, 1994, pages 1132-1142, XP002086282 page 1132	1,6,7, 11-24
X	VAN HOOGDALEM E.J. ET AL: "Intestinal drug absorption enhancement: an overview" PHARM. THER., vol. 44, 1989, pages 404-443, XP002086283 page 411; figure 412	1,2,6,7, 11-24

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

14 July 1999

Date of mailing of the international search report

21/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/00994

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AUNGST B. ET AL: "Enhancement of the intestinal absorption of peptides and non peptides" J. OF CONTROLLED RELEASE, vol. 41, - 1996 page 19-31 XP002086284 the whole document	1,2,6,7, 13-24
X	US 5 139 786 A (FERRINI PIER G ET AL) 18 August 1992 (1992-08-18) column 3; example 13	1-3,6,7, 13-24
X	WO 97 05903 A (DANBIOSYST UK ;WATTS PETER JAMES (GB); ILLUM LISBETH (GB)) 20 February 1997 (1997-02-20) page 23; example 12	1,2,6,7, 13-21
X	EP 0 223 369 A (BOOTS CO PLC) 27 May 1987 (1987-05-27) page 4, line 1 - line 32 page 15; examples 11,12	1-3,6,7, 13-21
X	US 5 190 748 A (BACHYN SKY MARIA O ET AL) 2 March 1993 (1993-03-02) column 12, line 58 - line 65	1-3,6,7, 13-21
X	PATENT ABSTRACTS OF JAPAN vol. 012, no. 148 (C-493), 7 May 1988 (1988-05-07) & JP 62 265226 A (FUJISAWA PHARMACEUT CO LTD), 18 November 1987 (1987-11-18) abstract	1,2,4,6, 7,22-24
X	& DATABASE WPI Section Ch, Week 8801 Derwent Publications Ltd., London, GB; Class B01, AN 88-002672 & JP 62 265226 A (FUJISAWA PHARM. CO LTD) abstract	1,2,4,6, 7,22-24
X	PATENT ABSTRACTS OF JAPAN vol. 016, no. 093 (C-0917), 6 March 1992 (1992-03-06) & JP 03 275633 A (TEIKOKU SEIYAKU KK), 6 December 1991 (1991-12-06) abstract	1,2,6,7, 13,14, 22-24
X	& DATABASE WPI Section Ch, Week 9204 Derwent Publications Ltd., London, GB; Class A12, AN 92-028863 & JP 03 275633 A (TEIKOKU SEIYAKU KK) abstract	1,2,6,7, 13,14, 22-24
A	FR 2 457 281 A (MERAM LAB) 19 December 1980 (1980-12-19) the whole document	8-11

INTERNATIONAL SEARCH REPORT

Int. national application No.

PCT/EP 99/00994

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: -7, 22, 23 because they relate to subject matter not required to be searched by this Authority, namely:

see FURTHER INFORMATION sheet PCT/ISA/210

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-7,22,23

Present claims 1,22,23 relate to an extremely large number of possible compounds defined by the expression "active ingredients which are hydrophilic or ionizable in physiological". The same remark applies for the "active ingredients" claimed in dependent claims 2-7.

Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed, namely the compounds claimed in claims 8-11 of the present application and the compounds of the examples. In the present case, the claims so lack support and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Moreover, it has to be pointed out that the claimed "absorption promoting agents" claimed in claim 1 are widely used in the manufacture of pharmaceutical preparations, in particular for oral use, and it would have been difficult, if not impossible to cite in the search report all the possible combinations of active ingredients and "absorption promoting agents".

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds, namely the "active ingredients" claimed in dependent claims 8-11 (see PCT Search Guidelines, PCT/GL2, Chapter III, 2.1, 3.6. and 3.7.; see Rule 33(3) PCT).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern	nal Application No
PCT/EP 99/00994	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5139786	A 18-08-1992	AU 638034 B AU 5870090 A CA 2020563 A EP 0407345 A JP 3044396 A MX 21453 A PT 94610 A		17-06-1993 10-01-1991 08-01-1991 09-01-1991 26-02-1991 31-01-1994 20-03-1991
WO 9705903	A 20-02-1997	AU 6705996 A CA 2227764 A EP 0843558 A GB 2318056 A, B NO 980047 A		05-03-1997 20-02-1997 27-05-1998 15-04-1998 06-01-1998
EP 0223369	A 27-05-1987	AT 59291 T AU 594264 B AU 6346586 A CA 1275930 A CS 8607083 A DK 453386 A, B, EG 17609 A FI 863976 A, B, GR 3001312 T IE 59134 B IN 164030 A JP 1741669 C JP 4028243 B JP 62111922 A KR 9400231 B PT 83474 A, B SU 1800996 A US 4786495 A		15-01-1991 01-03-1990 09-04-1987 06-11-1990 12-02-1990 04-04-1987 30-04-1995 04-04-1987 31-08-1992 12-01-1994 31-12-1988 15-03-1993 13-05-1992 22-05-1987 12-01-1994 01-11-1986 07-03-1993 22-11-1988
US 5190748	A 02-03-1993	AT 94765 T AU 625276 B AU 4538489 A CA 2003340 A DE 58905681 D DK 585889 A EP 0370481 A IE 63119 B IL 92357 A JP 2180837 A JP 7074165 B PH 26390 A YU 221889 A		15-10-1993 09-07-1992 31-05-1990 22-05-1990 28-10-1993 23-05-1990 30-05-1990 22-03-1995 07-10-1994 13-07-1990 09-08-1995 02-07-1992 28-05-1992
JP 62265226	A 18-11-1987	NONE		
JP 03275633	A 06-12-1991	NONE		
FR 2457281	A 19-12-1980	AT 372371 B AT 274580 A AU 535785 B BE 883468 A CA 1152100 A CH 647757 A DE 3019350 A		26-09-1983 15-02-1983 05-04-1984 24-11-1980 16-08-1983 15-02-1985 04-12-1980

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr. Application No
PCT/EP 99/00994

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2457281 A		GB 2051789 A, B	21-01-1981
		GR 68547 A	18-01-1982
		JP 1667644 C	29-05-1992
		JP 3017825 B	11-03-1991
		JP 56025146 A	10-03-1981
		JP 1818167 C	27-01-1994
		JP 3148219 A	25-06-1991
		JP 5024135 B	06-04-1993
		MX 9203363 A	01-07-1992
		NL 8002997 A, B,	25-11-1980
		OA 6606 A	31-08-1981
		US 4355043 A	19-10-1982
		ZA 8003051 A	24-06-1981